Medigene AG: Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform

Planegg/Martinsried (pta019/29.08.2024/11:00) - Medigene AG ( https://medigene.com/ ) (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced that the Company has been issued a patent by the European Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody.

In addition, a further patent has been granted by the Hong Kong Patent Office, protecting its inducible Medigene T cell receptor (iM-TCR) technology, a control mechanism to modulate efficacy and improve safety of T cell receptor engineered T cell (TCR-T) therapies. This complements previously granted patents from the European and Japan Patent Offices.

"Over the years, we have diligently established a comprehensive international intellectual property portfolio in key markets, which we anticipate will offer a substantial competitive edge. The patents granted for our proprietary JOVI and iM-TCR technologies enhance our End-to-End (E2E) Platform and underline our commitment to advancing TCR-guided therapies for the treatment of cancer," said Dolores Schendel, CSO at Medigene. "Central to our extensive expertise in T cell immunology is our capability to generate optimal TCRs. These potential best-in-class specific, sensitive, and safe (3S) TCRs show great potential for application across various modalities, including TCR-T therapies, as well as TCR-T cell engagers and TCR-natural killer cell therapies."

iM-TCR Technology

TCR-T therapies are effective at killing tumor cells, but if T cells are activated too much, they can become exhausted or die prematurely. This overactivation can also cause excessive immune responses, leading to inflammation and other harmful effects in the body. The iM-TCR technology addresses this issue by engineering the TCR so that its activity can be controlled by altering its presence or not, on the cell surface. This enables fine-tuned or "inducible" regulation of its activity against tumor cells, lowering the chances of inflammatory side effects. This technology enhances our current TCR-T therapy assets and has the potential to be applied to other TCR-guided approaches.

JOVI Technology

The selection of optimal 3S TCRs is crucial for developing TCR-guided therapies, such as TCR-T therapies, with enhanced safety and efficacy. The Company's innovative JOVI technology employs a high-throughput comparison approach, facilitating the enrichment of recombinant TCR-expressing T cells. This allows for straightforward comparison of their efficacy and safety profiles, ensuring the generation of superior TCR-T therapies, but also allows for their utilization in other TCR-guided modalities like TCR-T cell engagers or TCR-natural killer cell therapies.

--- end of press release ---

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities such as T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both its in-house product pipeline and partnering.

Medigene's lead TCR-T program MDG1015 is a potential best-in-class, TCR-T therapy to treat multiple solid tumor indications. The End-to-End Platform technologies enable armoring and enhancing of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure the T cell drug product composition maximizes safety, efficacy and durability of response. Medigene's MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4 2024. For more information, please visit http://www.medigene.com

About Medigene's End-to-End Platform

Medigene's approach to immunotherapy harnesses the immense power of natural T cell receptors. By combining these TCRs with different components of the immune system such as T cells, natural killer (NK) cells or a CD3 complex (TCE, T cell engager), highly specific, sensitive and safe modalities are formed to either complement and/or activate the body's defense systems against cancer. Medigene's comprehensive End-to-End (E2E) Platform is built on a foundation of proprietary and cutting-edge technologies, driving the development of highly specific TCR-guided therapies, including the latest advancements in TCR-T, TCR-NK and TCR-TCE drug products. The E2E Platform incorporates sophisticated TCR generation and optimization techniques, such as Allogeneic-HLA TCR Priming, and integrates advanced product armoring and enhancement features like PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins, and iM-TCR. In addition, the E2E Platform offers solutions to developing optimal cell therapy drug products for improved safety, efficacy and durability. Collaborations with partners like BioNTech, Regeneron and WuXi Biologics further underscore the platform's capabilities and its potential to revolutionize cancer treatment.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com ( https://medigene.sharepoint.com/sites/MDGCommunications/Freigegebene%20Dokumente/General/C.%20Press%20releases/PR_released/20240304_iM-TCR%20Japan%20patent/investor@medigene.com )). We will then delete your address from our distribution list.

(Ende)